COVID-19患者气管造口术的安全性与30天结局:前瞻性观察队列研究
本研究为英国伯明翰伊丽莎白女王医院的前瞻性观察队列研究,纳入164例COVID-19机械通气患者,其中100例接受气管造口术。结果显示气管造口组30天生存率85%,非造口组42%(RR=3.9,95%CI 2.3-6.4,P<0.0001);插管14天内造口与更短机械通气时间和ICU停留相关,且无医护人员感染COVID-19。
要点
- 气管造口组30天生存率85%,显著高于非造口组的42%。
- 插管14天内早期造口可缩短机械通气时间约6天和ICU停留约6.7天。
- 参与气管造口护理的医护人员无COVID-19感染发生。
核心结论
- 独立于COVID-19危重程度,接受气管造口术的患者30天生存率更高且ICU停留更短。
- 早期气管造口在COVID-19患者中似乎是安全的。
研究设计与样本
- 前瞻性观察队列研究,纳入英国伯明翰伊丽莎白女王医院2020年3月9日至4月21日ICU收治的164例COVID-19机械通气患者。
- 100例接受气管造口术(平均年龄55岁,标准差12;女性29%),64例未接受(年龄57岁,标准差14;女性25%)。
- 主要结局为30天生存率,校正严重器官功能障碍(APACHE-II评分>17)。
主要发现
- 气管造口组30天生存85/100(85%),非造口组27/64(42%),相对风险3.9(95%CI 2.3-6.4),P<0.0001。
- APACHE-II评分≥17的患者中,造口组生存68/100(68%),非造口组12/64(19%),P<0.001。
- 插管14天内行气管造口与更短机械通气时间相关(平均差6.0天,95%CI 3.1-9.0;P<0.0001)。
- 插管14天内行气管造口与更短ICU停留相关(平均差6.7天,95%CI 3.7-9.6;P<0.0001)。
- 无直接参与气管造口护理的医护人员感染COVID-19。
临床怎么用
- 对于COVID-19机械通气患者,气管造口术可考虑作为促进脱机和缩短ICU停留的策略。
- 在插管14天内早期实施气管造口可能安全且有益。
- 需建立专门的气道团队和协调教育计划以保障气管造口患者的病房管理。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The role of tracheostomy in coronavirus disease 2019 (COVID-19) is unclear, with several consensus guidelines advising against this practice. We developed both a dedicated airway team and coordinated education programme to facilitate ward management of tracheostomised COVID-19 patients. Here, we report outcomes in the first 100 COVID-19 patients who underwent tracheostomy at our institution. METHODS: This was a prospective observational cohort study of patients confirmed to have COVID-19 who required mechanical ventilation at Queen Elizabeth Hospital, Birmingham, UK. The primary outcome measure was 30-day survival, accounting for severe organ dysfunction (Acute Physiology and Chronic Health [APACHE]-II score>17). Secondary outcomes included duration of ventilation, ICU stay, and healthcare workers directly involved in tracheostomy care acquiring COVID-19. RESULTS: A total of 164 patients with COVID-19 were admitted to the ICU between March 9, 2020 and April 21, 2020. A total of 100 patients (mean [standard deviation] age: 55 [12] yr; 29% female) underwent tracheostomy; 64 (age: 57 [14] yr; 25% female) did not undergo tracheostomy. Despite similar APACHE-II scores, 30-day survival was higher in 85/100 (85%) patients after tracheostomy, compared with 27/64 (42%) non-tracheostomised patients {relative risk: 3.9 (95% confidence intervals [CI]: 2.3-6.4); P<0.0001}. In patients with APACHE-II scores ≥17, 68/100 (68%) tracheotomised patients survived, compared with 12/64 (19%) non-tracheotomised patients (P<0.001). Tracheostomy within 14 days of intubation was associated with shorter duration of ventilation (mean difference: 6.0 days [95% CI: 3.1-9.0]; P<0.0001) and ICU stay (mean difference: 6.7 days [95% CI: 3.7-9.6]; P<0.0001). No healthcare workers developed COVID-19. CONCLUSION: Independent of the severity of critical illness from COVID-19, 30-day survival was higher and ICU stay shorter in patients receiving tracheostomy. Early tracheostomy appears to be safe in COVID-19.
引用
- Safety and 30-day outcomes of tracheostomy for COVID-19: a prospective observational cohort study. Br J Anaesth. 2020. PMID: 32988602. doi:10.1016/j.bja.2020.08.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。